Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).


Clinical Trial Description

Behçet's disease is a severe chronic relapsing inflammatory disorder marked by oral and genital ulcers, uveitis and skin lesions, as well as varying multisystem involvement including the joints, blood vessels, central nervous system, and gastrointestinal tract. Oral ulcers are the initial symptom for most of Behçet's cases and are the single manifestation of the disease required for an official diagnosis, along with two other hallmark symptoms.

Ninety (90) patients will be enrolled in a randomized, parallel, double-blind, placebo-controlled study to evaluate the effectiveness of low dose natural human IFN α administered by the oral mucosal route in reducing the number, size, incidence and pain of oral ulcers in patients with Behçet's disease.

The clinical trial will consist of 3 groups of patients randomized in a 1:1:1 ratio to twice daily receive 2 lozenges containing 500 IU IFN α(2,000 IU daily, n=30), one active (500 IU) and one placebo lozenge (1,000 IU daily, n=30) or 2 placebo lozenges (n=30). Subjects will be monitored weekly over an initial 4 weeks of treatment and then bi-weekly over an additional 8 weeks of treatment. Medication will be self-administered as 2 lozenges taken twice daily (morning and evening). Oral lesions will be counted and measured at each study visit, and patients will answer a series of questionnaires. Results will be subjected to statistical analysis at the completion of the study, with change in total ulcer burden of a patient, a measurement of the total oral mucosal surface area involved with ulcerous lesions at each visit, serving as the primary endpoint. The total ulcer burden from each treated visit will be compared to the baseline total ulcer burden and the amount of change determined. Patients with a 75% decrease in total ulcer burden will be considered responders. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00483184
Study type Interventional
Source Nobel Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date April 2006
Completion date April 2008

See also
  Status Clinical Trial Phase
Completed NCT03274648 - Dietary Interventions and Butyrate Production in Behçet's Patients N/A
Terminated NCT01693653 - Tocilizumab for the Treatment of Behcet's Syndrome Phase 2
Completed NCT04961463 - Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model N/A
Completed NCT05142995 - Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
Recruiting NCT00931957 - Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease N/A
Completed NCT03514056 - Frequency of Fibromyalgia in Behcet Disease
Not yet recruiting NCT03771768 - Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease N/A
Terminated NCT03554161 - Tocilizumab for the Treatment of Refractory Behcet's Uveitis Phase 2
Recruiting NCT04738864 - Neuro-ultrasound Assessment in Behcet's Disease N/A
Completed NCT03264391 - Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
Completed NCT04386824 - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed NCT03962335 - Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study) N/A
Completed NCT01532570 - Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Phase 3
Not yet recruiting NCT04186559 - Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Phase 2
Terminated NCT04218565 - Golimumab for the Treatment of Refractory Behcet's Uveitis Phase 2
Not yet recruiting NCT03747354 - Assessment of Disease Activity in Behcet by Complete Blood Count N/A
Recruiting NCT05200715 - AutoInflammatory Disease Alliance Registry (AIDA)
Completed NCT05098678 - Zinc Supplementation and Behçet's Syndrome N/A
Completed NCT00866359 - A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Phase 2
Completed NCT05032248 - Uses of Tacrolimus in Behcet Disease N/A